Bipolar disorder treatment
WikiDoc Resources for
Bipolar disorder treatment
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Bipolar disorder is treatable. The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.
A variety of medications are used to treat bipolar disorder; most people with bipolar disorder require combinations of medications. There is little evidence, however, that alternative or complementary treatments used alone work well for the long-term treatment of the disorder.
Medications called mood stabilizers are used to prevent or mitigate manic or depressive episodes. Mood stabilizing medications with demonstrated efficacy include lithium, and anticonvulsants such as Depakote, carbamazepine, and lamotrigine. The atypical antipsychotics are all FDA approved for acute treatment of mania (quetiapine, olanzapine, risperidone). Generally speaking, mood stabilizing medications are more effective at treating or preventing manic episodes associated with bipolar disorder; however, some medications (i.e. lamotrigine, fluoxetine, quetiapine) have demonstrated efficacy for the treatment of bipolar depression.
In medicine, every medication has its side effects: bipolar disorder medications are no exception. It is important to point out that each medication is associated with a unique side effect profile.
Lithium may be associated with gastrointestinal upset (e.g. nausea, diarrhea), memory problems, weight gain and other side effects. Higher doses equal more side effects, but lower doses (within the therapeutic window) have little to no side effects.
Anticonvulsant medications commonly cause sedation, weight gain, electrolyte disturbances, or other side effects. If one cannot tolerate one of the anticonvulsants, it's advisable to try another anticonvulsant. Two or more anticonvulsants in combination can often result in a lower effective dose of each and lower side effects.
The side effect profile of the atypical antipsychotics vary widely between agents. Generally speaking, the most common side effects of the atypicals are sedation and metabolic disturbances (i.e. weight gain, dyslipidemia, hyperglycemia). Atypical antipsychotics may also cause extrapyramidal side effects and restlessness. Atypical antipsychotics also carry a risk of causing tardive dyskinesia; however, the risk with the newer atypical agents is much less than the risk associated with older antipsychotics (e.g. haloperidol). The risk of TD is thought to be proportionate to the duration of neuroleptic/antipsychotic use (roughly 5% per year in non-elderly patients treated with older antipsychotics). Patients and physicians need to be careful to watch for symptoms of this side effect carefully so that an antipsychotic can be reduced in dosage, or changed to another medication, before the condition progresses. The physician should, of course, be consulted about any change in dosage.
A recent large-scale study  found that severe depression in patients with bipolar disorder responds no better to a combination of antidepressant medications and mood stabilizers than it does to mood stabilizers alone. Furthermore, this federally funded study found that antidepressant use does not hasten the emergence of manic symptoms in patients with bipolar disorder.
Medications work differently in each person, and it takes considerable time to determine in any particular case whether a given drug is effective at all, since bipolar disorder is by nature episodic, and patients may experience remissions whether or not they receive treatment. For this reason, neither patients nor their doctors should expect immediate relief, although psychosis with mania can respond quickly to anti psychotics, and bipolar depression can be alleviated quickly with electroconvulsive therapy (ECT). Many doctors emphasize that patients should not expect full stabilization for at least 3-4 weeks (some antidepressants, for example, take 4-6 weeks to take effect), and should not give up on a medication prematurely, nor should they discontinue medication with the disappearance of symptoms as the depression may return.
Compliance with medications can be a major problem, because some people as they become manic lose the awareness of having an illness, and they therefore discontinue medications. Patients also often quit taking medication when symptoms disappear, erroneously thinking themselves "cured", and some people enjoy the effects of unmedicated hypomania.
Depression does not respond instantaneously to resumed medication, typically taking up to 6 weeks to respond. Mania may disappear slowly, or it may become depression.
Other reasons cited by individuals for discontinuing medication are side effects, expense, and the stigma of having a psychiatric disorder. In a relatively small number of cases stipulated by law (varying by locality but typically, according to the law, only when a patient poses a threat to himself or others), patients who do not agree with their psychiatric diagnosis and treatment can legally be required to have treatment without their consent. Throughout North America and the United Kingdom, involuntary treatment or detention laws exist for severe cases of bipolar disorder and other mental illnesses where there is a potential for harm to oneself or others.
Lithium salts had long been used as a first-line treatment for bipolar disorder. In ancient times, doctors would send their mentally ill patients to drink from "alkali springs" as a treatment. They did not know it, but they were really prescribing lithium, which was present in high concentration in the waters. The therapeutic effect of lithium salts appears to be entirely due to the lithium ion, Li+.
The two lithium salts used for bipolar therapy are lithium carbonate (mostly) and lithium citrate (sometimes). Approved for the treatment of acute mania in 1970 by the Food and Drug Administration (FDA), lithium has been an effective mood-stabilizing medication for many people with bipolar disorder. Lithium is also noted for reducing the risk of suicide. Although lithium is among the most effective mood stabilizers, persons taking it may experience side effects similar to the effects of ingesting too much table salt, such as high blood pressure, water retention, and constipation. Regular blood testing is required when taking lithium to determine the correct lithium levels since the therapeutic dose is close to the toxic dose.
The mechanism of lithium salt treatment is believed to work as follows: some symptoms of bipolar disorder appear to be caused by the enzyme inositol monophosphatase (IMPase), an enzyme that splits inositol monophosphate into free inositol and phosphate. It is involved in signal transduction and is believed to create an imbalance in neurotransmitters in bipolar patients. The lithium ion is believed to produce a mood stabilizing effect by inhibiting IMPase by substituting for one of two magnesium ions in IMPase's active site, slowing down this enzyme.
Lithium orotate is used as an alternative treatment to lithium carbonate by some individuals with bipolar disorder, mainly because it is available without a doctor's prescription. It is sometimes sold as "organic lithium" by nutritionists, as well as under a wide variety of brand names. There seems to be little evidence for its use in clinical treatment in preference to lithium carbonate. Individuals with bipolar disorder have complained that it is much weaker than lithium carbonate and, therefore, less effective.
Lithium has problems with its side effects, including hand trembling and intolerance of hot weather. Cogentin is sometimes used to control the trembling, but itself causes sedation. Lithium has a very narrow window of effectiveness. Below that level it has no effect, and above it is toxic. For that reason blood must be sampled frequently to determine if the proper blood level is currently present.
Anticonvulsant mood stabilizers
Anticonvulsant medications, particularly valproate and carbamazepine, have been used as alternatives or adjuncts to lithium in many cases. Valproate (Depakote, Epival) was FDA approved for the treatment of acute mania in 1995, and is now considered by some doctors to be the first line of therapy for bipolar disorder. A similar medication, valproic acid (Depakene) is also used. For some, it is preferable to lithium because its side effect profile seems to be less severe, compliance with the medication is better, and fewer breakthrough manic episodes occur. However, valproate is not as effective as lithium in preventing or managing depressive episodes, so patients taking valproate may also need an antidepressant as an adjunct medicinal therapy.
New research suggests that different combinations of lithium and anticonvulsants may be helpful. Anticonvulsants are also used in combination with antipsychotics. Newer anticonvulsant medications, including lamotrigine and oxcarbazepine, are also effective as mood stabilizers in bipolar disorder. Lamotrigine is particularly promising, as it alleviates bipolar depression and prevents recurrence at higher rates.,
Zonisamide (trade name Zonegran), another anticonvulsant, also may show promise in treating bipolar depression according to Frederick K. Goodwin M.D. on a recent Medscape webcast titled "The Accurate Diagnosis and Long-Term Treatment of Bipolar Depression" to view the webcast click here. (free reg required).
Topiramate has not done well in clinical trials; it seems to help a few patients very much but most not at all. It appears to be useful in some treatment resistant cases and for anxiety issues when clonazepam cannot be prescribed. Gabapentin has failed to distinguish itself from placebo as a mood stabilizer.
According to studies conducted in Finland in patients with epilepsy, valproate may increase testosterone levels in teenage girls and produce polycystic ovary syndrome in women who began taking the medication before age 20. Increased testosterone can lead to polycystic ovary syndrome with irregular or absent menses, obesity, and abnormal growth of hair. Therefore, young female patients taking valproate should be monitored carefully by a physician. However, the therapeutic dose for a patient taking valproate for epilepsy is much higher than the therapeutic dose of valproate for an individual with bipolar disorder.
Atypical antipsychotic drugs
The newer atypical antipsychotic drugs such as risperidone, quetiapine, and olanzapine are often used in acutely manic patients, because these medications have a rapid onset of psychomotor inhibition, which may be lifesaving in the case of a violent or psychotic patient. Parenteral and orally disintegrating (in particular, Zydis wafers) forms are favoured in emergency room settings. These drugs can also be used as adjunctives to lithium or anticonvulsants in refractory bipolar disorder and in prevention of mania recurrence. They also have fewer side effects, and are often used in place of lithium, in combination with an antidepressant, an anticonvulsant, or both.
In light of recent evidence, olanzapine (Zyprexa) has been FDA approved as an effective monotherapy for the maintenance of bipolar disorder. A head-to-head randomized control trial in 2005 has also shown olanzapine monotherapy to be just as effective and safe as lithium in prophylaxis. Eli Lilly and Company also offers Symbyax, a combination of olanzapine and fluoxetine.
Ziprasidone (Geodon) and aripriprazole (Abilify) also show promise according to Gary Sachs M.D. of Harvard's Massachusetts General Hospital Bipolar Clinic and Research Program. (View the webcast above at the Bipolar Clinic and Research Program link).
The atypical antipsychotics have some potential for causing weight gain and diabetes, and in larger doses over long periods may simetimes create tardive dyskinesia, though with much lesser probability than with the typical antipsychotics, such as Thorazine, Stelazine, or Haliperidol (Haldol.)
Modafinil (Provigil) and Pramipexole (Mirapex) show promise in treating the cognitive deterioration related to bipolar depression.  In addition Riluzole, an ALS treatment, has been shown to be effective treatment. The breast cancer medicine tamoxifen has shown quick response to manic phases.
Certain types of psychotherapy, used in combination with medication, may provide some benefit in the treatment of bipolar disorders. Psychoeducation has been shown to be effective in improving patients' compliance with their lithium treatment. Several studies of family therapy report it can improve family communication, social functioning and lithium compliance, though it appears to be effective mainly on females. Evidence for the efficancy of other psychotherapies is absent or weak, often not being performed under randomized and controlled conditions. Well-designed studies have found interpersonal and social rhythm therapy to be ineffective.
Although medication and psychotherapy cannot cure the illness, therapy can often be valuable in helping to address the effects of disruptive manic or depressive episodes that have hurt a patient's career, relationships or self-esteem. Therapy is available not only from psychiatrists but from social workers, psychologists and other licensed counselors.
Electroconvulsive therapy (ECT) is sometimes used to treat severe bipolar depression in cases where other treatments have failed and is 60 to 70 percent effective. Although it has proved to be a highly effective treatment, doctors are reluctant to use it except as a treatment of last resort because of the side-effects and possible temporary memory loss complications of ECT, particularly when repeated treatments ("maintenance ECT") are needed.
Omega-3 fatty acids
Omega-3 fatty acids may also be used as a treatment for bipolar disorder, particularly as a supplement to medication. An initial clinical trial by Stoll et al. produced positive results . However, since 1999 attempts to confirm this finding of beneficial effects of omega-3 fatty acids in several larger double-blind clinical trials have produced inconclusive results. It was hypothesized that the therapeutic ingredient in omega-3 fatty acid preparations is eicosapentaenoic acid (EPA) and that supplements should be high in this compound to be beneficial. Omega-3 fatty acids may be found in fish, fish oils, algae, and to a lesser degree in other foods such as flaxseed, flaxseed oil and walnuts. Some researchers have found that only omega-3 fatty acids derived from fish products shows efficacy, whereas omega-3 fatty acids derived flaxseed oil or supplements are ineffective.
Complementary and alternative treatments
Complementary and/or non-Western treatments, such as acupuncture, meditation, yoga and orthomolecular therapy, are used by some people with bipolar disorder, and some research shows one, particularly yoga in mild bipolar depression, may have some scientific merit. However, further studies are needed to indicate which complementary therapies are effective and for what illness type and for whom.
Self help in understanding
Understanding the symptoms, when they occur and ways to better control them has given many people diagnosed with bipolar a chance. A helpful hint is to remember that this is not a major illness, rather a benefit in most controlled cases.
A ketogenic diet similar to the diet used for pediaric epilepsy was thought to have mood stabilizing and antidepressant effects.  Stanford University Medical School attempted a study using a ketogenic diet protocol on bipolar patients. However due to the lack of ability to attract subjects the trial was never started. Studies have shown it to have anti-depressant properties in rats.
Some claim that THC can relieve depressive phases through its euphoriant action, while the tranquilizing effects of THC can alleviate manic phases. Others note that marijuana may increase anxiety and depression, consequently lowering one's threshold for future mood episodes.
One recent online survey questioned the notion that marijuana smoking increases a user's risk for depression.  The authors of the study show that marijuana users reported fewer somatic symptoms and daily users reported less depressed mood and more positive affect than non-users. These self-report data suggest that adults apparently do not increase their risk for depression by using marijuana. Many find that the calming sedation associated with the use of cannabis helps to alleviate depression.
Current medical marijuana pharmaceuticals (such as dronabinol, marketed as Marinol) exist in the U.S. while Sativex, a whole-plant cannabis extract, is currently being marketed in Canada, the UK and Spain. Sativex is used for various illnesses, such as MS, cancer, and depression . Individuals who want to access pharmaceutical cannabis, however, may not be able to receive it due to drug laws against marijuana. Although illegal in many places around the world, cannabis remains easy to grow and purchase. See legal issues of cannabis for more information.
On the other hand cannabis may not be a very suitable medicine for people with bipolar disorder, as scientists have shown cannabis may trigger psychosis, hallucinations or psychotic illnesses in individuals who have an existing predisposition to mental illness or are already suffering from it. 
Summing up, while there may be an application for cannabis in some cases of bipolar illness, this view is currently the subject of much controversy and in need of more research.
Antidepressants in bipolar disorder: the controversy
There is increasing evidence that certain antidepressants are contraindicated in bipolar disorder. Fredrick K. Goodwin M.D.(1), coauthor of Manic Depressive Illness with Kay Redfield Jamison PhD and the NIMH's Robert M. Post (2) gleaned evidence by comparing the life charts of individuals with BP I and BP II who were medicated with certain mood stabilizers only versus any combination of those mood stabilizers plus certain antidepressants. The life chart trends indicated that use of certain antidepressants (over months to years) caused a long-term worsening of the illness over the life course compared to certain mood stabilizers alone in both bipolar I and bipolar II disorders. Specifically, they observed increased cycle frequency, increased mood episode severity, the emergence of mixed states and more treatment-resistant (difficult to treat) bipolar disorder.
Obvious forms of stress include having too much to do, too much complexity, conflicting demands, etc. There are also stresses that come from the absence of elements such as human contact, a sense of achievement, constructive creative outlets, and occasions or circumstances that will naturally elicit positive emotions. Stress reduction will involve reducing things that cause anxiety and increasing those that generate happiness. It is not enough to just reduce the anxiety.
- ↑ Sachs, G. et al. (2007). "Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression". New England Journal of Medicine 356 (17): 1711–1722. doi:10.1056/NEJMoa064135. (Abstract freely available; Subscription required for full text)
- ↑ Fawcett, J., Golden, B., & Rosenfeld, N. (2000). New Hope for People with Bipolar Disorder. Roseville, CA: Prima Health.
- ↑ Baldessarini RJ, Tondo L, Hennen J. (2003). "Lithium treatment and suicide risk in major affective disorders: update and new findings". Journal of Clinical Psychiatry 64 (Suppl 5): 44–52. (Subscription required)
- ↑ Epilepsy Drug Lamictal Appears Effective For Bipolar Depression
- ↑ Lamotrigine for Bipolar Disorder PsychEducation.org
- ↑ RH Belmaker, Yuly Bersudsky, Alex Mishory and Beersheva Mental Health Center (2005). Valnoctamide in Mania. ClinicalTrials.gov. United States National Institutes of Health. Retrieved on 25 February, 2006.
- ↑ Belmaker, R. H. (July 29, 2004). "Bipolar Disorder". The New England Journal of Medicine 351 (5): 476–486. doi:10.1056/NEJMra035354.
- ↑ Now Approved: ZYPREXA for maintenance therapy for bipolar disorder. Official Zyprexa Website.
- ↑ Tohen, Mauricio; Waldemar Greil, Joseph R. Calabrese, Gary S. Sachs, Lakshmi N. Yatham, Bruno Müller Oerlinghausen, Athanasios Koukopoulos, Giovanni B. Cassano, Heinz Grunze, Rasmus W. Licht, Liliana Dell’Osso, Angela R. Evans, Richard Risser, Robert W. Baker, Heidi Crane, Martin R. Dossenbach and Charles L. Bowden (July 2005). "Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial". American Journal of Psychiatry 162 (7): 1281–1290. doi:10.1176/appi.ajp.162.7.1281.
- ↑ Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study Biopsychiatry.
- ↑ Zarate CA Jr, Singh JB (2007). "Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study.". Bipolar Disord. 9 (6): 561–70. doi:10.1111/j.1399-5618.2007.00530.x. PMID 17845270.
- ↑ Cochran S. (1984). "Preventing medical non-compliance in the outpatient treatment of bipolar affective disorder," J Consult Clin Psychol, 52:873–8.
- ↑ 13.0 13.1 Parikh SV, Kusumakar V, Haslam DRS, Matte R, Sharma V, Yatham LN (1997). "Psychosocial interventions as an adjunct to pharmacotherapy in bipolar disorder," Can. J. Psychiatry, 42 (Suppl. 2): 74S-78S
- ↑ 14.0 14.1 Goodnick, Paul J. (2002). ""Psychosocial Treatments for Bipolar Disorder: Is There Evidence That They Work?," in Bipolar Disorder, Vol. 5 (WPA Series in Evidence & Experience in Psychiatry), p338. ISBN 978-0471560371.
- ↑ Frank E, Swartz HA, Mallinger AG et al. (1999). "Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality," J Abnorm Psychol, 108(4):579-587.
- ↑ Stoll, Andrew L.; Emanuel Severus, Marlene P. Freeman, Stephanie Rueter, Holly A. Zboyan, Eli Diamond, Kimberly K. Cress, Lauren B. Marangell (May 1999). "Omega 3 fatty acids in bipolar disorder. A preliminary double-blind, placebo-controlled trial". Archives of General Psychiatry 56 (5): 407–412. doi:10.1001/archpsyc.56.5.407.
- ↑ Osher Y, Bersudsky Y, Belmaker RH. (2005). "Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study". Journal of Clinical Psychiatry 66 (6): 726–9. PMID 15960565.
- ↑ Denson, Thomas F.; Mitchell Earleywine (June 17, 2005). "Decreased depression in marijuana users". Addictive Behaviors. doi:10.1016/j.addbeh.2005.05.052.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies